Many fragments derived from collagen I degradation come to serum during bone resorption. The characterization of these fragments and the development of assays that can measure them are the basis of most of the biochemical markers of bone resorption. One of these fragments consists of two cross-linked amino acid sequences derived from the C-terminal telopeptide region of type I collagen ␣ 1 chains. Fragments containing the sequence EKAH-DGGR (CTX), with a DG site being either nonisomerized (␣-CTX) or ␤-isomerized (␤-CTX) were identified. Pyridinoline, deoxypyridinoline, and other cross-links linked both telopeptides ( Fig. 1) (1 ). Recent reports have suggested that the proportions of nonisomerized and ␤-isomerized fragments depend on bone age (1 ) .
There are two available assays that can measure the ␤-isomer form of the CTX epitope: urinary CrossLaps TM ELISA (2 ), and Serum CrossLaps One Step ELISA (3 ), both from Osteometer (Denmark). The urinary assay is a polyclonal (rabbit) antibody assay for which the minimal requirement for detection is the presence of the amino acid sequence EKAH␤DGGR. According to the manufacturer, only one strand is necessary for recognition. Thus, among the products in Fig. 1 , this assay would be able to detect compounds 2 and 3. The serum assay is based on two highly specific monoclonal antibodies, also directed against the amino acid sequence EKAH␤DGGR; however, according to the manufacturer, the minimal requirement of this assay is the presence of two chains of ␤-CTX, which must be cross-linked. In this case, among the products in Fig. 1 , the serum assay would be able to detect only compound 3.
The urinary version of this assay has provided a sensitive and specific index of bone resorption that is able to predict the outcome of antiresorptive therapy and bone loss rate in postmenopausal women (2 ) . Recent works have demonstrated that Serum CrossLaps can also be used to predict women with the highest risk of developing osteoporosis and to monitor antiresorptive therapy (4 ) .
Based on the different antigenicity of the two assays, the aim of the present work was to compare the usefulness of urinary ␤-CTX (CrossLaps ELISA; Osteometer) and serum ␤-CTX (Serum CrossLaps One Step ELISA), in the detection of changes of bone resorption between females 16 -19 years of age and females 21-24 years of age. Urine (second morning void) and serum samples were collected in the morning on the same day.
Variations in the serum concentrations of the bone isoenzyme of alkaline phosphatase (Tandem ® -R Ostase ® IRMA; Hybritech) were used as control. Thirty-one healthy control females, age 19 Ϯ 2.3 years (range, 16 -24 years) were studied. None of them were receiving any treatment known to affect calcium metabolism. The study was approved by the Ethics Committee of our hospital. The concentrations of the biochemical markers studied are shown in Table 1 . As expected, bone alkaline phosphatase (bAP) was significantly lower in the females Ͼ19 years of age than in the females Յ19 years of age. Serum ␤-CTX also decreased significantly with age. However, urinary ␤-CTX in the older group was similar to that of the younger group. We observed a significant linear correlation between serum ␤-CTX and serum bAP (P ϭ 0.0296); however, we did not find a significant correlation between urinary ␤-CTX and serum bAP (P ϭ 0.2297), although serum ␤-CTX correlated with urinary ␤-CTX (P ϭ 0.0211).
One possible explanation of the differences found between serum and urinary assays of ␤-CTX could be the Technical Briefs different antigenicity of both assays. Accordingly, the serum assay seems to be more restrictive than the urinary assay for detecting products derived from the telopeptide region of collagen type I. The decrease in bone remodeling that occurs in older girls with respect to younger girls is a generally accepted fact. In accordance with the results found in this work in ␤-CTX and bAP concentrations, it would be possible suggest that serum ␤-CTX assay (Serum CrossLaps) reflects better than urinary ␤-CTX assay (CrossLaps) the changes in bone remodeling that take place in young girls. It is possible that, independent of the differences attributable to renal clearance, the serum assay can be more specific for bone than the urinary assay because of the different antigenicity of the assays.
More work is necessary to investigate this point, but the observed differences between the two ␤-CTX methods constitute an interesting point to consider when selecting a serum or a urinary assay to perform a particular study. The California newborn screening program requires that all newborns be screened for selected hemoglobinopathies. Dried blood spot (DBS) specimens are analyzed using an automated 2-min cation-gradient HPLC method that is sensitive and specific (1, 2 ) . The standardized method selected by the State allows the screening program to match the quantitative analytical performance of the assay at eight private contract laboratories and a central laboratory. Information technology is designed to derive phenotypes automatically and to use quantitative acceptability limits for quality control and proficiency testing.
Distribution of Hemoglobin F, A, S, C, E, and D Quantities in 4 Million
The distribution of hemoglobin (Hb) quantities determined by cation-exchange HPLC in cord blood specimens has been published previously (3, 4 ) . We have determined the frequency distributions for the analysis of DBS specimens using the rapid HPLC screening method. In this study, we examined screening data reported on 4 million nontransfused newborns tested within 2 days of birth. The frequency distributions were determined for the percentages of Hb concentrations in 14 phenotypes containing Hbs F, A, S, C, E, and D. The frequency distributions are available on request. The medians only are given in Table 1 .
The percent concentrations in the current study are lower than the published cord blood data by 15% for all Hb F and by a median 36% for the Hb in other hetero-and homozygous patterns (range, 22-40%). This may be caused by differences in the HPLC methodology and by chemical degradation of Hb during formation of the dried blood spots (5, 6 ). Approximately 28 -34% of the total area of the DBS chromatograms is eluted before the quantified species F, A, S, C, E, and D. These rapidly eluted species include unidentified degradation products and F 1 , as well as a compound that elutes, in some samples, at the void volume and is correlated with Hb Barts (leftmost peak in the dashed curve in Fig. 1 ).
The relationships found among the concentrations of adult Hbs in carrier patterns are consistent with published cord blood data. As a fraction of the total adult Hb present in the newborn blood spots, the results are 0.41-0.45 for Hbs S, C, and D in patterns FAS, FAC, and FAD, and 0.27 for Hb E in FAE.
The chromatographic integration parameters have been adjusted to assure that all Hbs are reported in the pattern when the concentrations exceed 1% for Hbs F, A, E, and D and 0.5% for Hbs S and C (1 ). In the event that concentrations are below the limits, the software will continue to include the Hb in the pattern as long as the signal-to-noise criteria are satisfied (1 ). We have found that the one- 
